SQZ has demonstrated delivery of a wide range of materials into numerous primary cell types with minimal impact on function and viability. "This differentiating capability enables one to engineer diverse cellular functions and create a broad range of cell therapies for multiple therapeutic areas."
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze